# Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Toni K. Choueiri,Masatoshi Eto,Robert J. Motzer,Ugo De Giorgi,Tomáš Büchler,Naveen S. Basappa,María José Méndez-Vidal,Sergei Tjulandin,Se Hoon Park,Bohuslav Melichar,Thomas E. Hutson,C. Alemany,Bradley A. McGregor,Thomas Powles,Viktor Grünwald,B. Yа. Alekseev,Sun Young Rha,Evgeny Kopyltsov,Anil Kapoor,Teresa Alonso Gordoa,Jeffrey C. Goh,Michael Staehler,Jaime R. Merchan,Ran Xie,Rodolfo F. Perini,Kalgi Mody,Jodi A. McKenzie,Camillo Porta |
| Citations | 167 |
| DOI | 10.1016/s1470-2045(23)00049-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.sciencedirect.com/science/article/pii/S1470204523000499/pdf |
| OpenAlex ID | https://openalex.org/W4322422773 |
| PMID | 36858721 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Toni K. Choueiri](https://scholariq.org/researchers/toni-k-choueiri/)
- [Masatoshi Eto](https://scholariq.org/researchers/masatoshi-eto/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.